The Amarylidacea alkaloid galanthamine (1a) is an acetylcholinesterase inhibitor that has been evaluated as a potential agent for the treatment of Alzheimer's disease. We report a very efficent synthesis of (±)‐galanthamine [(±)‐1a] from readily available isovanillin and tyramine. We have separated racemic galanthamine into its diastereoisomeric (1S)‐camphanate esters and obtained both natural (‐)‐ and unnatural (+)‐galanthamine by lithium aluminum hydride removal of the acyl group.
No takes yet. Share an insight, caveat, or question.
Szewczyk et al. (1995) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: